HCS PHARMA
Loos
About HCS PHARMA
HCS Pharma is a biotechnology company focused on in vitro R&D, specializing in high content (HCA) and high throughput (HCS) cell imaging screening. HCS Pharma sells products based on BIOMIMESYS® technology, and develops its own 3D cellular models in its proprietary BIOMIMESYS® extracellular matrix. BIOMIMESYS® 3D culture technology faithfully reproduces the natural microenvironment of cells in 3D, to ensure more predictive results from in vitro studies, to reduce the time and cost of R&D, and animal testing in pharmaceutical, nutraceutical and cosmetic companies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $26.0M
- Last round: Initial Coin Offering (ICO) (Mar 2022)
- Website: hcs-pharma.com
- Phone: 33 769 999 137
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/hcs-pharma-133005 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.